PL2121025T3 - Sposoby i kompozycje dla dostarczania czynnika terapeutycznego - Google Patents

Sposoby i kompozycje dla dostarczania czynnika terapeutycznego

Info

Publication number
PL2121025T3
PL2121025T3 PL08705994T PL08705994T PL2121025T3 PL 2121025 T3 PL2121025 T3 PL 2121025T3 PL 08705994 T PL08705994 T PL 08705994T PL 08705994 T PL08705994 T PL 08705994T PL 2121025 T3 PL2121025 T3 PL 2121025T3
Authority
PL
Poland
Prior art keywords
delivery
compositions
methods
therapeutic agent
therapeutic
Prior art date
Application number
PL08705994T
Other languages
English (en)
Polish (pl)
Inventor
Sveinbjorn Gizurarson
James Arp
Raouf Ghaderi
Michael E. Lusty
Gregory G. Plucinski
Mehdi Yazdi
Original Assignee
Hananja Ehf
University Of Iceland
Ikano Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hananja Ehf, University Of Iceland, Ikano Therapeutics Inc. filed Critical Hananja Ehf
Publication of PL2121025T3 publication Critical patent/PL2121025T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL08705994T 2007-01-19 2008-01-18 Sposoby i kompozycje dla dostarczania czynnika terapeutycznego PL2121025T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IS8593 2007-01-19

Publications (1)

Publication Number Publication Date
PL2121025T3 true PL2121025T3 (pl) 2017-09-29

Family

ID=39512543

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08705994T PL2121025T3 (pl) 2007-01-19 2008-01-18 Sposoby i kompozycje dla dostarczania czynnika terapeutycznego

Country Status (11)

Country Link
EP (2) EP3150230A1 (enExample)
JP (5) JP5877939B2 (enExample)
CN (3) CN106420614A (enExample)
AU (1) AU2008206105B2 (enExample)
CA (1) CA2676010C (enExample)
DK (1) DK2121025T3 (enExample)
ES (1) ES2611995T3 (enExample)
HU (1) HUE031463T2 (enExample)
IL (1) IL199904A (enExample)
PL (1) PL2121025T3 (enExample)
WO (1) WO2008089426A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720716D0 (en) * 2007-10-23 2007-12-05 York Pharma Plc Novel formulation
GB2481407B (en) * 2010-06-22 2012-05-23 Special Products Ltd A rapid onset liquid midazolam composition for buccal administration
SG194927A1 (en) * 2011-05-13 2013-12-30 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
CN111278425B (zh) * 2017-09-11 2024-06-11 耶路撒冷希伯来大学伊萨姆研究开发有限公司 用于向脑部经鼻给药药物和用于全身作用的组合物和方法
JP2019099557A (ja) * 2017-11-28 2019-06-24 日本化薬株式会社 ベンダムスチンを含有する溶液製剤
WO2019226753A1 (en) 2018-05-25 2019-11-28 Ucb Biopharma Sprl Benzodiazepine formulations
CN111388481A (zh) * 2020-03-20 2020-07-10 浙江美华鼎昌医药科技有限公司 一种咪达唑仑和丙戊酸钠的药物组合物及其制备方法
CN118161457A (zh) * 2020-12-04 2024-06-11 四川科瑞德制药股份有限公司 磷苯妥英钠固体组合物、冻干方法、及其用途
CN113274482B (zh) * 2021-06-07 2023-09-05 穆琳 缩宫素或其衍生物在制备治疗或改善贫乳的制剂中的用途以及组合物
WO2024142091A1 (en) * 2022-12-26 2024-07-04 Cipla Limited Stable aqueous injectable formulation of flucytosine
WO2025115019A1 (en) * 2023-11-30 2025-06-05 Padagis Israel Pharmaceuticals Ltd. Stable nitroglycerin formulations

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4153689A (en) 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
EP0259383B1 (de) * 1986-03-10 1991-01-23 Kurt Dr. Burghart Pharmazeutikum sowie verfahren zu seiner herstellung
US4782047A (en) 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
JP3219096B2 (ja) 1990-05-10 2001-10-15 ニコメド ファーマ エイエス n―グリコフロール類及びn―エチレングリコール類を含有する医薬製剤
US5338732A (en) * 1991-06-18 1994-08-16 Bristol-Myers Squibb Company Megestrol acetate formulation
GB9125699D0 (en) 1991-12-03 1992-01-29 Glaxo Group Ltd Device
US5897880A (en) * 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
IL127769A (en) * 1996-07-03 2006-10-31 Alza Corp Non-aqueous protic preparations of peptides
KR100715513B1 (ko) * 1999-07-26 2007-05-08 에스케이 코오포레이션 경비 항경련성 조성물
KR100360827B1 (ko) * 1999-08-14 2002-11-18 주식회사 삼양사 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
DE19940236A1 (de) 1999-08-25 2001-03-08 Pfeiffer Erich Gmbh & Co Kg Spender mit manuell betätigbarer Ausbringeinrichtung
US20020037319A1 (en) * 1999-11-08 2002-03-28 Alan Drizen Drug preparations
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
WO2002013886A2 (en) 2000-08-15 2002-02-21 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
WO2003099264A1 (en) * 2002-05-23 2003-12-04 Umd, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
JP4542743B2 (ja) * 2002-12-26 2010-09-15 Kdl株式会社 ピリドン誘導体の溶液状医薬組成物
JP2007070225A (ja) * 2003-07-25 2007-03-22 Yukako Fujinaga クロストリジウム属菌由来成分を含む医薬製剤
WO2005027977A2 (en) * 2003-09-22 2005-03-31 Agis Industries (1983) Ltd. Diclofenac compositions for the treatment of skin disorders
WO2005044199A2 (en) * 2003-11-05 2005-05-19 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
GB0400804D0 (en) * 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
JP4746856B2 (ja) * 2004-08-12 2011-08-10 三笠製薬株式会社 ピラゾロン系製剤
US20060110415A1 (en) * 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
WO2006075125A1 (en) * 2005-01-14 2006-07-20 Camurus Ab GnRH ANALOGUE FORMULATIONS
US20070021411A1 (en) * 2005-05-11 2007-01-25 Cloyd James C Supersaturated benzodiazepine solutions and their delivery
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
CA2669705A1 (en) * 2006-11-21 2008-05-29 Novartis Ag Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure

Also Published As

Publication number Publication date
JP5877939B2 (ja) 2016-03-08
CA2676010A1 (en) 2008-07-24
JP2010516696A (ja) 2010-05-20
IL199904A (en) 2014-07-31
AU2008206105B2 (en) 2014-04-03
JP2017048250A (ja) 2017-03-09
JP6084277B2 (ja) 2017-02-22
CA2676010C (en) 2016-05-17
WO2008089426A3 (en) 2009-02-12
JP2016029117A (ja) 2016-03-03
ES2611995T3 (es) 2017-05-11
CN106420614A (zh) 2017-02-22
CN101678112B (zh) 2016-08-31
WO2008089426A2 (en) 2008-07-24
JP6295314B2 (ja) 2018-03-14
AU2008206105A1 (en) 2008-07-24
DK2121025T3 (en) 2017-01-30
EP2121025B1 (en) 2016-11-02
EP3150230A1 (en) 2017-04-05
EP2121025A2 (en) 2009-11-25
CN106389330A (zh) 2017-02-15
JP2013231089A (ja) 2013-11-14
CN101678112A (zh) 2010-03-24
HUE031463T2 (en) 2017-07-28
JP2017155060A (ja) 2017-09-07
IL199904A0 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
PL2121025T3 (pl) Sposoby i kompozycje dla dostarczania czynnika terapeutycznego
AP2965A (en) Therapeutic compositions and the use thereof
AP2490A (en) Therapeutic compositions and the use thereof
EP2242527A4 (en) DEVICES AND METHODS FOR ADMINISTERING A THERAPEUTIC AGENT THROUGH PNEUMOSTOMY
ZA200904936B (en) Benefit agent delivery compositions
IL202684A0 (en) Anti-cd20 therapeutic compositions and methods of use thereof
EP2180873A4 (en) THERAPEUTIC DENTAL COMPOSITION AND RELATED METHODS
IL207569A0 (en) Compositions and methods for drug delivery
EP2046430A4 (en) ADMINISTRATION OF ANTI-THERAPY
EP2101855A4 (en) ADMINISTRATION OF ANTI-THERAPY
GB0625659D0 (en) Therapeutic compounds and their use
GB0609492D0 (en) Therapeutic agents
GB0608928D0 (en) Therapeutic agents
GB0601962D0 (en) Therapeutic agents
IL195764A0 (en) Compositions and methods for drug delivery
EP2010162A4 (en) COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT
IL198723A0 (en) Methods and compositions for therapeutic treatment
IL197235A0 (en) Therapeutic compositions
GB0616214D0 (en) Therapeutic Agents
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
EP2236148A4 (en) MEDIinic agent for HELICOBACTER treatment
GB0611152D0 (en) Therapeutic agents
EP2236145A4 (en) PHARMACEUTICAL COMPOSITION AND ACTIVE INGREDIENT COMBINATION
EP2231163A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USE